Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

3.7 3.9

No patient experienced viral rebound (defined as >1 log10 increase from a prior measurement) through week 4. In accordance with the study protocol, four patients (three genotype 1a patients receiving placebo plus SOC and one genotype 1b patient receiving ANA598 plus SOC) discontinued either ANA598 or placebo at week 4 due to failing to reach at least 1 log10 viral load decline.

Preliminary Safety Assessment

Safety and tolerability from the interim analysis appeared similar between the active and placebo arms, with reported adverse events generally typical for interferon and ribavirin, although conclusions regarding longer-term safety and tolerability cannot be made until additional results over longer duration from this trial and future clinical trials in more patients are known. There were no discontinuations due to adverse events. Eight patients reported rash through the interim analysis date, seven mild and one moderate. For the six of twenty-nine patients (21%) receiving ANA598 plus SOC who reported rash, all cases were mild. For the two of fifteen patients (13%) receiving placebo plus SOC who reported rash, one case was mild and one case was moderate. There were no clinically meaningful changes in safety laboratory values and no changes in safety monitoring were recommended by the DMC in association with escalation to 400 mg bid.

Phase II Combination Study

In the ongoing Phase II study, treatment-naïve genotype 1 patients are to receive ANA598 or placebo in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) for 12 weeks at dose levels of 200 mg or 400 mg both given twice daily (bid), each with a loading dose of 800 mg bid on day one. After week 12, patients are to continue receiving SOC. Patients who achieve undetectable levels of virus at weeks 4 and 12 will be randomized to stop all treatment at week 24 or 48.
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  BC Technical, the ... acquired Polaris Medical Imaging, a leader in sales, service ... strategic acquisition allows BC Technical to continue to expand ... within MR and CT modalities. "We ... said Mark Alvarez , president and CEO of ...
(Date:8/29/2014)... Does your doctor know what you,re smoking?  Chances ... marijuana to the over 112,000 currently registered patients under ... the other roughly 20,300+ active physicians listed with the Colorado ... – even though a poll in February 2014 showed 51% ... tried it. "With marijuana legalization underway, every ...
(Date:8/29/2014)... WASHINGTON , Aug. 29, 2014 Diseases ... a generation ago are returning. Measles was declared ... cases in 2014 as of August 15—the highest incidence ... public health department declared whooping cough a problem ... children are getting sick and dying from these preventable ...
Breaking Medicine Technology:BC Technical Acquires Polaris Medical Imaging 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... (Nasdaq: THOR ), a world leader in ... restore failing hearts, said today that it will be ... On Wednesday, September 22, Thoratec will participate in the ... vice president and chief financial officer, will provide an ...
... 16 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs ... data do not adequately demonstrate that the potential benefits ... in a population of overweight and obese individuals to ...
Cached Medicine Technology:Thoratec to Present at Upcoming Investor Conferences 2Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 2Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 3Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting 4
(Date:8/30/2014)... Acne is a common problem millions of American ... more than a daily nuisance, for some, it can have a ... can even lead to dramatic mood swings and depression. , ... clear up their skin. In some cases, that can make the ... and error, those on a quest for clearer skin can now ...
(Date:8/30/2014)... August 30, 2014 Continuing to meet ... is expanding with the addition of a new doctor ... who has provided leading-edge skin care in Grand Rapids ... , “As a doctor, my passion is making ... partnering with Forefront Dermatology, I’m better able to focus ...
(Date:8/30/2014)... medication commonly used to treat gout, before and ... potential complications from this type of surgery, but ... effects, according to a study published by ... online to coincide with its presentation at the ... after cardiac surgery include postpericardiotomy syndrome (the occurrence ...
(Date:8/30/2014)... New York, New York (PRWEB) August 30, 2014 ... consolidated litigation for transvaginal mesh lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ... the company’s request to sever four cases selected ... to an Order issued on August 18, 2014, ... Southern District of West Virginia disagrees with Boston ...
(Date:8/30/2014)... August 30, 2014 One of the most ... is the gluten-free diet. Originally meant for sufferers of gluten ... catchall for people who are looking to get healthier by ... only is this kind of information erroneous, it also exposes ... because of a drastic change in their food consumption ...
Breaking Medicine News(10 mins):Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Expanding Care at the Forefront of Dermatology 2Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2
... a Rich Source to Fill the "E Gap", ... the U.S. population does not meet the current intake,recommendation ... the,September 2008 Journal of Nutrition(). The article recognized almonds ... this nutrient gap and the,authors concluded that vitamin E, ...
... Receive Benefits of, Member Emergency Assistance Plans to ... 11 As predictions increase for Hurricane,Ike to become ... the Texas Gulf Coast,Blue Cross and Blue Shield of ... may potentially be affected., "Quick access to health ...
... CHENGDU, China, Sept. 11 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, ... manufacturer and,supplier of modernized traditional Chinese medicine ... the Company has received approval from,the Chinese ... produce Laonian,Kechuan Tablets in the dosage form ...
... the Delft University of Technology in the Netherlands, global shortages ... of the past. This is the message from Prof. Bert ... in an article in university journal Delta . ... a shortage of radio isotopes which means that patients will ...
... serious consequences for the children,s growth, health, and survival. ... women and their children in Bangladesh and Nicaragua and ... exposed to violence grow less and are sick more ... paediatrician, the Department of Women,s and Children,s Health, monitored ...
... and global marketer of vascular access and fluid ... four weeks after the company,s introduction of its ... from Boston Scientific. They are: 1) an ... inudstry,s only dual-safety EZ Huber® Infusion Needle Set; ...
Cached Medicine News:Health News:E-mergency? Majority of U.S. Consumers Lack Essential Vitamin E 2Health News:Preparations by Blue Cross and Blue Shield of Texas Will Assist Members Affected by Hurricane Ike 2Health News:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets 2Health News:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets 3Health News:Delft University of Technology patent for manufacturing radio isotopes 2Health News:New Vascular Access Medical Devices Launched by Navilyst Medical 2Health News:New Vascular Access Medical Devices Launched by Navilyst Medical 3Health News:New Vascular Access Medical Devices Launched by Navilyst Medical 4Health News:New Vascular Access Medical Devices Launched by Navilyst Medical 5
... most comprehensive family of lightweight standard ... incision, Glaucoma filtration, and Vitreoretinal uses. ... with minimal tissue trauma and minimal ... are available in 18, 20, and ...
... Centuries of German Craftsmanship have ... in the world. Ocutek now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
Medicine Products: